Tags

Type your tag names separated by a space and hit enter

Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.
Hepatology. 2005 Jul; 42(1):63-71.Hep

Abstract

Cannabinoids present in Cannabis sativa (marijuana) exert biological effects via cannabinoid receptors CB1 and CB2. We recently demonstrated that CB1 and CB2 receptors regulate progression of experimental liver fibrosis. We therefore investigated the impact of cannabis smoking on fibrosis progression rate in patients with chronic hepatitis C (CHC). Two hundred seventy consecutive untreated patients with CHC of known duration undergoing liver biopsy were studied. Demographic, epidemiological, metabolic, and virological data were recorded, and detailed histories of cannabis, alcohol, and tobacco use over the span of hepatitis C virus infection were obtained. Fibrosis stage, steatosis, and activity grades were scored according to Metavir system. Patients were categorized as noncannabis users (52.2%), occasional users (14.8%), or daily users (33.0%), and the relationship between cannabis use and fibrosis progression rate (FPR) or fibrosis stage was assessed. On multivariate analysis, six factors were independently related to a FPR greater than 0.074 (median value of the cohort): daily cannabis use (OR = 3.4 [1.5-7.4]), Metavir activity grade A2 or higher (OR = 5.4 [2.9-10.3]), age at contamination of more than 40 years (OR = 10.5 [3.0-37.1]), genotype 3 (OR = 3.4 [1.5-7.7]), excessive alcohol intake (OR = 2.2 [1.1-4.5]), and steatosis (OR = 2.0 [1.0-4.1]). Daily cannabis use was also an independent predictor of a rapid FPR (>0.15) (OR = 3.6 [1.5-7.5]). Finally, severe fibrosis (> or =F3) was also predicted by daily cannabis use (OR = 2.5 [1.1-5.6]; P = .034), independently of Metavir activity grade, excessive alcohol intake, age at liver biopsy, steatosis, and tobacco smoking. In conclusion, daily cannabis smoking is significantly associated with fibrosis progression during CHC. Patients with ongoing CHC should be advised to refrain from regular cannabis use.

Authors+Show Affiliations

Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris XII, Créteil, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15892090

Citation

Hézode, Christophe, et al. "Daily Cannabis Smoking as a Risk Factor for Progression of Fibrosis in Chronic Hepatitis C." Hepatology (Baltimore, Md.), vol. 42, no. 1, 2005, pp. 63-71.
Hézode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology. 2005;42(1):63-71.
Hézode, C., Roudot-Thoraval, F., Nguyen, S., Grenard, P., Julien, B., Zafrani, E. S., Pawlotsky, J. M., Pawlostky, J. M., Dhumeaux, D., Lotersztajn, S., & Mallat, A. (2005). Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology (Baltimore, Md.), 42(1), 63-71.
Hézode C, et al. Daily Cannabis Smoking as a Risk Factor for Progression of Fibrosis in Chronic Hepatitis C. Hepatology. 2005;42(1):63-71. PubMed PMID: 15892090.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. AU - Hézode,Christophe, AU - Roudot-Thoraval,Françoise, AU - Nguyen,Son, AU - Grenard,Pascale, AU - Julien,Boris, AU - Zafrani,Elie-Serge, AU - Pawlotsky,Jean-Michel, AU - Pawlostky,Jean-Michel, AU - Dhumeaux,Daniel, AU - Lotersztajn,Sophie, AU - Mallat,Ariane, PY - 2005/5/14/pubmed PY - 2005/8/3/medline PY - 2005/5/14/entrez SP - 63 EP - 71 JF - Hepatology (Baltimore, Md.) JO - Hepatology VL - 42 IS - 1 N2 - Cannabinoids present in Cannabis sativa (marijuana) exert biological effects via cannabinoid receptors CB1 and CB2. We recently demonstrated that CB1 and CB2 receptors regulate progression of experimental liver fibrosis. We therefore investigated the impact of cannabis smoking on fibrosis progression rate in patients with chronic hepatitis C (CHC). Two hundred seventy consecutive untreated patients with CHC of known duration undergoing liver biopsy were studied. Demographic, epidemiological, metabolic, and virological data were recorded, and detailed histories of cannabis, alcohol, and tobacco use over the span of hepatitis C virus infection were obtained. Fibrosis stage, steatosis, and activity grades were scored according to Metavir system. Patients were categorized as noncannabis users (52.2%), occasional users (14.8%), or daily users (33.0%), and the relationship between cannabis use and fibrosis progression rate (FPR) or fibrosis stage was assessed. On multivariate analysis, six factors were independently related to a FPR greater than 0.074 (median value of the cohort): daily cannabis use (OR = 3.4 [1.5-7.4]), Metavir activity grade A2 or higher (OR = 5.4 [2.9-10.3]), age at contamination of more than 40 years (OR = 10.5 [3.0-37.1]), genotype 3 (OR = 3.4 [1.5-7.7]), excessive alcohol intake (OR = 2.2 [1.1-4.5]), and steatosis (OR = 2.0 [1.0-4.1]). Daily cannabis use was also an independent predictor of a rapid FPR (>0.15) (OR = 3.6 [1.5-7.5]). Finally, severe fibrosis (> or =F3) was also predicted by daily cannabis use (OR = 2.5 [1.1-5.6]; P = .034), independently of Metavir activity grade, excessive alcohol intake, age at liver biopsy, steatosis, and tobacco smoking. In conclusion, daily cannabis smoking is significantly associated with fibrosis progression during CHC. Patients with ongoing CHC should be advised to refrain from regular cannabis use. SN - 0270-9139 UR - https://www.unboundmedicine.com/medline/citation/15892090/Daily_cannabis_smoking_as_a_risk_factor_for_progression_of_fibrosis_in_chronic_hepatitis_C_ L2 - https://doi.org/10.1002/hep.20733 DB - PRIME DP - Unbound Medicine ER -